Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
They correspond to U.K.'s short-acting psychedelic therapies developer Small Pharma's (OTC:DMTTF) open-label Phase 1b study assessing the joint work of its "native" DMT compound, SPL026 and selective serotonin reuptake inhibitors (SSRIs.) Read more HERE.
Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program, Legal Medical Psilocybin Access For Veteran Approved
Canadian not-for...
Login or create a forever free account to read this news
Sign up/Log in